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Abstract
Background: Bacillus probiotics health benefits have been until now quite poorly studied in the elderly population.
This study aimed to assess the effects of Bacillus subtilis CU1 consumption on immune stimulation and resistance to
common infectious disease (CID) episodes in healthy free-living seniors.
Results: One hundred subjects aged 60–74 were included in this randomized, double-blind, placebo-controlled,
parallel-arms study. Subjects consumed either the placebo or the probiotic (2.109 B. subtilis CU1 spores daily) by
short periodical courses of 10 days intermittently, alternating 18-day course of break. This scheme was repeated 4
times during the study. Symptoms of gastrointestinal and upper/lower respiratory tract infections were recorded
daily by the subjects throughout the study (4 months). Blood, saliva and stool samples were collected in a
predefined subset of the first forty-four subjects enrolled in the study. B. subtilis CU1 supplementation did not
statistically significantly decrease the mean number of days of reported CID symptoms over the 4-month of study
(probiotic group: 5.1 (7.0) d, placebo group: 6.6 (7.3) d, P = 0.2015). However, in the subset of forty-four randomized
subjects providing biological samples, we showed that consumption of B. subtilis CU1 significantly increased fecal
and salivary secretory IgA concentrations compared to the placebo. A post-hoc analysis on this subset showed a
decreased frequency of respiratory infections in the probiotc group compared to the placebo group.
Conclusion: Taken together, our study provides evidence that B. subtilis CU1 supplementation during the winter
period may be a safe effective way to stimulate immune responses in elderly subjects.
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Background
Viral respiratory and gastrointestinal infections are a pre-
dominant cause of morbidity and mortality in the elderly
whose ageing immune system contributes significantly to
poor outcomes [1]. Ageing is associated with a decline of
innate and adaptive immune responses. For innate dys-
function, it has been described that the function of natural
killer cells, dendritic cells [2], macrophages [3] and
neutrophils [4] decrease in the elderly. Moreover, age-
dependent thymic involution leads to the reduction of
circulating naive T cells and the increase frequency of
regulatory, memory and effector T cells [5, 6]. A dra-
matic reduction in B cell repertoire associated with a
decreased systemic antibody response to vaccination
has been observed in the elderly population [7] show-
ing that the B cell compartment is also affected by
ageing [8, 9]. In addition, the production of secretory
IgA (SIgA) at the mucosal surfaces decreases with age
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and can lead to an increased risk of infection [10, 11].
SIgA, the predominant immunoglobulin class in human
external secretions, is a key element in the maintenance of
gut microbiota homeostasis and in the protection of
gastrointestinal and respiratory tracts against pathogens
[12]. Moreover, it has been also shown that the age-
dependent modifications of the composition of the gut
microbiota also contribute to the defective local and sys-
temic immune defenses in the elderly population [13, 14].
The development of strategies aimed at counterbalan-
cing the immune frailty in the elderly is a major challenge
for 21st century medicine. Nutritional supplementation,
including probiotics, in this population may help maintain
immune function either by direct interaction with the host
immune system or indirectly by re-equilibrating the gut
microbiota [15–17].
Probiotics have been defined as ‘Live microorganisms
which when administered in adequate amounts confer a
health benefit on the host’ [18]. Lactobacillus and Bifido-
bacterium are the most commonly used bacterial pro-
biotics. Fermented milk or dairy products containing
Lactobacillus have shown effects on duration or fre-
quency of respiratory and gastrointestinal infections
[19–21] and reduced the risk of the common cold in
healthy elderly subjects [22]. Mañé et al. [23] showed
significant trends in reducing infection incidence and
mortality due to pneumonia in institutionalized elderly
subjects treated with two Lactobacillus plantarum
strains. Some trials showed that Lactobacillus and Bifi-
dobacterium probiotics could increase influenza vaccin-
ation immune responses in the elderly [24–27].
Endospore formers such as Bacillus species are interest-
ing because their spores resist the acid barrier of the stom-
ach and are stable for long periods in commercial food
products [28]. Bacilli, considered as gut commensals, have
been used as probiotics for prophylaxis of human gastro-
intestinal disorders, to prevent recurrent respiratory infec-
tions or as an adjunct to antibiotic use [29–34].
Probiotics have been suggested to protect against infec-
tious diseases by several strain-dependant mechanisms
[35, 36] including secretion of anti-pathogen substances,
competitive exclusion of pathogens, maintenance of mu-
cosal integrity and stimulation of systemic or mucosal
immune responses [35–39]. Bacillus species have been
shown to produce antimicrobial substances [40, 41], to
enhance epithelial gut barrier functions [42, 43] and
stimulate cytokine [43–45] and SIgA in humans [46].
In this study we evaluated the beneficial effect of Bacil-
lus subtilis CU1 administration in an elderly population.
This probiotic displays immunostimulating properties and
antagonizes gastrointestinal pathogen infection by produ-
cing antimicrobial substances such as amicoumacins
(Racedo SM & Urdaci MC, unpublished observations).
This randomized, double-blind placebo-controlled study
investigated the effect of probiotic strain B. subtilis CU1
intake on resistance to common infectious disease (CID),
notably by measuring mean cumulative number of days
with CID in healthy free-living seniors (individuals over
60 years old). As secondary endpoints, the study examined
the effect of B. subtilis CU1 intake on the stimulation of
the mucosal and systemic immune response by measuring
intestinal and salivary SIgA levels and serum cytokine
levels, respectively, in a subset of 44 subjects.
Results
Subject characteristics
One hundred thirty two (132) subjects were screened for
study eligibility, and 100 were randomized to the pro-
biotic group (N = 50) or to the placebo group (N = 50)
(Fig. 1). All enrolled subjects completed the study with-
out major deviation.
The baseline characteristics for the population are
presented in Table 1. The data from the initial clinical
examination were normal for all volunteers. Mean age
observed in the probiotic group (63.3 (2.8) years of
age) and placebo group (63.0 (2.4) years of age) were
consistent with inclusion criteria. The influenza vac-
cination rates in the subjects, seasonal influenza and
influenza A, from the beginning of the influenza vac-
cination season (September) were respectively 16. 0 %
and 8.0 % in probiotic group and 14.0 % and 12.0 %
in placebo group. A good mean compliance was ob-
served (>99 % in both groups).
Clinical outcomes on the whole study population
Considering the whole study population (N = 100), the
mean number of days with CID symptoms over the 4-
month study period was 5.1 (7.0) d in the probiotic
group and 6.6 (7.3) d in the placebo group (P = 0.2015)
(Table 2). The percentage of subjects reporting at least
one CID episode during the study was 58.0 % in the
probiotic group (N = 29/50) and 66.0 % in the placebo
group (N = 33/50) (P = 0.4106). The risk to report an
Fig. 1 Flow chart of subjects
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infectious episode in the probiotic group was 12 %
lower than in the placebo group (Relative Risk = 0.88
[1.20;0.65]). There was no statistically significant differ-
ence between the probiotic and the placebo groups in
mean duration, intensity, and frequency of CID during
the observation period (P = 0.2361, P = 0.7400, and P =
0.3290 respectively).
Clinical outcomes on the subset of 44 subjects (post-hoc
analysis)
Considering the subset of the 44 subjects, the mean
number of days with CID symptoms was 4.5 (7.3)
days in the probiotic group and 7.3 (8.2) days in the
placebo group (P = 0.1101) (Table 2). In this subset,
the percentage of subjects reporting at least one infectious
episode during the study was 50.0 % (N = 11/22) in the
probiotic group and 72.7 % (N = 16/22) in the placebo
group (P = 0.1260). The risk to report an infectious epi-
sode was 31 % lower in probiotic group than in placebo
group (Relative Risk = 0.69 [1.12;0.42]). There was no dif-
ference in mean duration, intensity and frequency of CID
during the observation period between the probiotic and
placebo groups (P = 0.2361, P = 0.7400, and P = 0.1117
respectively). In the same subset (N = 44), the frequency of
respiratory infections was significantly lower in the pro-
biotic group compared to the placebo group (P = 0.0323):
a mean number of 0.6 (0.7) respiratory infections was ob-
served in the probiotic group vs. 1.1 (0.9) in the placebo
group. The mean number of days with respiratory CID
Table 1 Baseline subject characteristics of the whole population
(N = 100), by product group
Probiotic group Placebo group
(N = 50) (N = 50)
Mean SD Mean SD
Age (years) 63.3 2.8 63.0 2.4
Body weight (kg) 60.5 22.5 57.4 21.2















Mean values and standard deviations; numbers and percentages
Table 2 Effect of probiotic (B. subtilis CU1) and placebo consumption on clinical outcomes of infectious diseases










Mean SD Mean SD Mean SD Mean SD
Mean number of days with CID 5.1 7.0 6.6 7.3 0.2015a 4.5 7.3 7.3 8.2 0.1101a
Mean duration of CID (d) 5.0 4.6 5.3 4.1 0.2361a 5.8 5.6 5.7 4.1 0.2361a
Mean intensity of CID 8.1 5.0 7.6 4.4 0.7400a 9.0 6.2 8.8 5.3 0.7400a
CID frequency 1.0 1.2 1.2 1.2 0.3290a 0.8 1.0 1.3 1.2 0.1117a
Subjects with at least one CID 0.4106b 0.1260b
n 29 33 11 16
% 58 · 0 66 · 0 50 · 0 72 · 7
Mean number of days with RI 4.4 6.9 6.2 7.2 0.1027a 3.7 6.9 6.6 7.9 0.0818a
Mean duration of RI (d) 5.9 5.0 5.6 4.2 0.9043a 6.8 6.3 6.1 4.3 0.9325a
Mean intensity of RI 9.3 5.3 7.8 4.6 0.1428a 11.1 6.3 9.3 5.6 0.3473a
RI frequency 0.7 0.9 1.1 1.2 0.1181a 0.6 0.7 1.1 0.9 0.0323a
Subjects with at least one RI 0.1609b 0.0701b
n 24 31 10 16
% 48.0 62.0 45.5 72.7
Data are presented for the whole population (N = 100) and the subset of population with biology analysis (N = 44). (Mean values and standard deviations;
numbers and percentages)
Statistical differences were evaluated using Wilcoxon-Mann-Whitney’s test or Savage’s test according to the asymmetry of data (a), or logistic regression model (b)
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symptoms was 3.7 (6.9) in the probiotic group and 6.6
(7.9) in the placebo group (P = 0.0818).
Immunological parameters (subset of 44 subjects)
Mucosal response
Fecal and salivary SIgA response. SIgA is widely used as
marker of mucosal immunity in clinical studies [47]. Re-
markably, we observed a significantly higher concentra-
tion of SIgA in stools in the probiotic group compared
to the placebo group after 10 d of product consumption
(probiotic group: 2062.6 (1161.8) μg/ml; placebo group:
1249.5 (863.8) μg/ml; P = 0.0038) (Fig. 2). The increased
SIgA levels were still observed at the end of consumption
and 18 d after the end of B. subtilis CU1 consumption
(probiotic group: 2424.4 (1252.3) μg/ml; placebo group:
1297.1 (953.7) μg/ml; P = 0.0032). Furthermore, fecal
SIgA concentrations significantly increased between
pre- and post-supplementation with B. subtilis CU1
after 10 days of probiotic consumption (P = 0.0012). Ele-
vated levels persisted 18 d after the last probiotic con-
sumption (P = 0.0008). SIgA concentrations in stools were
not statistically affected by placebo consumption. In
addition, a significantly higher concentrations of salivary
SIgA were observed in the probiotic group compared to
the placebo group at the end of consumption and 18 d
after the end of B. subtilis CU1 consumption (probiotic
group: 940.4 (446.0) μg/mL; placebo group: 650.1 (343.5)
μg/mL; P = 0.0219) (Fig. 3).
Systemic response
Blood IFN response (Fig. 4). No statistically significant
difference in IFN-gamma concentrations were observed
between groups, after 10 d of probiotic consumption
(V1 + 10 d) (probiotic group: 9.7 (8.1) pg/mL; placebo
group: 31.8 (92.4) pg/mL; P = 0.0981). However, IFN-
gamma concentrations significantly increased in the pro-
biotic group from first pre- to post- supplementation,
after 10 d of probiotic consumption (probiotic group at
V1: 6.9 (5.0) pg/mL; P = 0.0090), while no significant
change was observed in the placebo group. No statistically
significant differences in the plasma concentrations of cy-
tokines (IL-1beta, IL-4, IL-6, IL-8, IL-10, IL-12p70, IgA,
and TNF-alpha) were measured between the probiotic and
the placebo groups from pre- to post- supplementation.
Numeration of B. subtilis in the stools (subset of 44
subjects)
An increase in Bacillus spore concentrations were ob-
served in stools of subjects from the probiotic group but
not in the placebo group (Table 3). Molecular typing using
the OPL12 primer showed the presence of the B. subtilis
CU1 strain in stools as opposed to the placebo group and
demonstrates the viability of the probiotic strain.
Stool cytotoxicity (subset of 44 subjects)
No statistically significant difference was measured
in the cytotoxicity levels in stools between the
Fig. 2 Concentrations of secretory IgA in stools. Fecal SIgA
concentrations were assessed in subjects from the subset of
population (N = 44), at baseline (V1), after 10 days of consumption
of study products (V1 + 10 d) and at the end of the study (V3).
Values are means, with standard error of means represented by
vertical bars. Fecal SIgA concentrations were significantly higher in
the probiotic group compared to the placebo group (**P <0.01),
and significantly increased in the probiotic group during the study
(†† P < 0.01, ††† P < 0.001)
Fig. 3 Concentrations of secretory IgA in saliva. Salivary SIgA
concentrations were assessed in subjects from the subset of
population (N = 44), at the end of the study (V3). Values are means,
with standard error of means represented by vertical bars. Salivary
SIgA concentration was significantly higher in the probiotic group
compared to the placebo group (*P <0.05)
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probiotic group (94.25 % (34.46) of viability) and
placebo group (93.98 % (31.06) of viability), after 10
d of product consumption (P = 0.6328). These data
confirm the absence of stool cytotoxicity induced by
B. subtilis CU1.
Safety (whole study population)
Investigators reported 108 adverse events in the pro-
biotic group and 85 in the placebo group (P = 0.8369).
There were no abnormal values of biological parameters
at the end of the study, and no clinically significant vari-
ation was observed during the study, on renal and hepatic
functions.
Discussion
The current controlled study was designed to evaluate
the effect of probiotic strain B. subtilis CU1 consump-
tion (2.109spores/d) on immune system stimulation and
resistance to respiratory and gastrointestinal CID in
healthy free-living seniors with known past histories of
CID during the winter period. The demographic charac-
teristic of the volunteers, the duration of study and the
compliance to product consumption were similar for
probiotic and placebo groups. The probiotic product
was safe and well tolerated. An increase in B. subtilis
CU1 concentration was observed in stools after intake of
the probiotic product, which suggests survival of the
strain in the gastrointestinal tract and is consistent with
high compliance of study assessed by product consump-
tion. The probiotic did not significantly affect CID in the
whole population (N = 100). In the subset of 44 subjects,
and as planned in the protocol, biological explorations
were performed. These analyses showed that B. subtilis
CU1 significantly increased the levels of SIgA in stools
(P = 0.0032) and saliva (P = 0.0219) in comparison to pla-
cebo and induced significantly higher levels of serum
IFN-gamma (P = 0.0090). Furthermore, a post-hoc ana-
lysis in this subset of subjects showed a statistically
lower frequency of respiratory infections in the probiotic
group compared to the placebo group (P = 0.0323).
We readily acknowledge several limitations to our
study. Except for respiratory infections in the subset of
44 subjects, the clinical efficacy of oral administration of
probiotic B. subtilis CU1 did not reach statistical signifi-
cance. Consequently the study hypothesis was not reached,
i.e., to observe a difference of 3 d in CID episodes between
the two groups. However the statistical power of our
study was lower than expected and B. subtilis supple-
mentation tended to decrease the mean number of
days with respiratory CID symptoms compared to the
placebo group in the subset of 44 subjects (post-hoc
analysis). In addition, B. subtilis CU1 supplementation
significantly reduced the frequency of respiratory in-
fections in this subset of population (P = 0.0323). This
subgroup was originally planned in the protocol only for
biological analysis and the clinical efficacy observed in this
subset, while not confirmed in the whole population,
might be explained either by chance only or by the higher
infection rates at the beginning of the clinical study (i.e.,
beginning of winter season, which is likely to correspond
to the highest CID exposure period).
B. subtilis CU1 stimulates systemic immune response
In the present study, we observed that supplementation
with B. subtilis CU1 stimulated systemic immune re-
sponse in seniors by significantly increasing serum IFN-
gamma in the probiotic group following first B. subtilis
supplementation. Concentrations of other measured
Fig. 4 Concentrations of IFN-gamma in blood. IFN-gamma
concentrations were assessed in subjects from the subset of
population (N = 44), at baseline (V1), after 10 days of consumption of
study products (V1+ 10 d) and at the end of the study (V3). Values are
means, with standard error of means represented by vertical bars.
IFN-gamma concentrations were significantly increased in the
probiotic group between V1 and V1 + 10 d (††P <0.01)
Table 3 Bacterial counts of Bacillus spores in the stools of the
subset population (N = 44)
Whole population (N = 100)
Probiotic group (N = 22) Placebo group (N = 22)
Mean SD Mean SD
V1 2.5.103 3.0.103 2.5.103 5.4.103
V1 + 10 days 1.9.107 1.1.107 2.3.103 5.1.103
V3 7.5.103 1.5.104 3.0.103 4.4.103
Mean values and standard deviations
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serum cytokines and serum IgA were not significantly
modified. These results are in accordance with previous
mouse studies using B. subtilis CU1 (Racedo SM &
Urdaci MC, unpublished observations). Huang et al. [48]
also found that Bacillus strains could stimulate systemic
and intestinal IFN-gamma production in mice. This Pro-
Th1 cytokine plays a role in the host defense against
several infectious diseases, including viral infection and
has a variety of immune functions such as stimulation of
macrophages and natural killer cells [49, 50]. Different
studies have emphasized the importance of IFN-gamma
production for the protective effect of probiotics against
influenza infection [51, 52]. Further investigations in B.
subtilis CU1’s capability in increasing serum IFN-gamma
levels and the strengthening of the systemic anti-viral
and anti-bacterial immune defenses in the elderly popu-
lation would be interesting.
B. subtilis CU1 enhances intestinal and respiratory
mucosal immune responses
An important finding of the present study was that,
compared to placebo, the oral intake of B. subtilis CU1
resulted in higher SIgA production in the healthy se-
niors. Ten days of probiotic intake were sufficient to
increase stool SIgA levels 65 % in treated seniors com-
pared to placebo. Moreover, an increased level of 87 %
was maintained at least 18 days after the last probiotic
administration. Previous controlled clinical trials have
shown that the intake of probiotic bacteria (mainly
Lactobacillus and Bifidobacterium) stimulates mucosal
immune systems by enhancing fecal IgA [53, 54].
Kabeerdoss et al. [54] observed an increase of fecal IgA
during probiotic intake with a subsequent decrease
after cessation of administration of the probiotic.
We assessed SIgA concentrations in saliva at the end
of the 18-d follow up period. B. subtilis CU1 intake pro-
duced a 45 % increase in SIgA relative to placebo group.
Since B. subtilis CU1 had been shown to increase IgA
producing B cells in Peyer’s patches in mice (Racedo SM
& Urdaci MC, unpublished observations), one can pos-
tulate that B. subtilis CU1 consumption strengthens the
generation of α4β7+IgA+ B cells in the Peyer’s patches of
the small intestine of elderly subjects. The homing of
these IgA producing B cells to the intestinal mucosa and
the salivary glands [55] most probably accounts for the
high SIgA levels measured in the feces and saliva of the
probiotic group. In the elderly, only one previous study
has shown that oral administration of heat-killed Lacto-
bacillus pentosus b240 produced an increase in salivary
IgA secretion [16]. Importantly, it has been shown, in
mice, that 50 % increase production of intestinal SIgA to
a bacterial toxin significantly increased the vaccine-
induced protection directed against the toxin [56]. Add-
itionally, it has also been shown that a 20 % increase in
production of total SIgA in saliva is associated with a de-
crease in the incidence of colds and flu-like symptoms in
humans [57, 58]. Therefore, increased SIgA levels of
87 % and 45 % in faeces and saliva respectively are most
probably of physiological significance in ameliorating the
health status of seniors receiving B. subtilis CU1.
Taken together, these findings show the utility of oral
administration of probiotic B. subtilis CU1 to increase
mucosal immune responses. The increased SIgA levels
in the intestine and saliva might contribute to strength-
ening the mucosal anti-viral and anti-bacterial immune
defenses of the elderly population. It has to be noted
that secretion of salivary SIgA has been shown to be im-
paired by stress such as academic stress or intensive
physical exercise [59, 60]. Therefore interesting future
work would be to investigate whether B. subtilis CU1
stimulation of mucosal immune system might be benefi-
cial in the general population, notably in a population
under stress.
King et al. [61] recently published a meta-analysis and
systematic review showing that Lactobacillus spp. and
Bifidobacterium spp. strains brought by food products or
supplements significantly lowered the number of days of
acute respiratory infections in a healthy population of
children and adults and shortened acute respiratory
infectious periods. There are only few studies in the
elderly and the present one is the first to indicate a trend
toward a reduction of CID by a B. subtilis strain in this
population. Additional larger clinical trials have to be
conducted to confirm these clinical outcomes.
Conclusions
Despite the absence of significant results on CID in
the whole population, the present study showed that
consumption of B. subtilis CU1 significantly increased
intestinal and salivary SIgA and serum IFN-gamma
levels in a subset senior population. It suggests that
daily B. subtilis CU1 supplementation during the win-
ter months may be a safe effective way to stimulate
systemic and mucosal immune responses of the eld-
erly. However, no firm conclusion can be made about
the effect of B. subtilis CU1 supplementation on CID.
Additional larger clinical trials have to be conducted
to confirm these clinical outcomes.
Methods
Ethics, consent and permissions
The study was approved by the West IV Ethics Committee
for Human Research and the French Health Products
Safety Agency (AFSSAPS), France and was performed in
accordance with the principles of the Declaration of
Helsinski, of Good Clinical Practice (Directive ICH E-6, 24
November 2006), and current French regulations (Code de
Santé Publique, Titre II du livre Premier). All participants
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had given their written informed consent before inclusion
in the study.
Study subjects
One hundred (100) healthy free-living adults between
60 and 74 years of age, without any known congenital
or immune defects, severe chronic disease or allergies
and reporting at least two CID episodes during the
previous winter period were recruited. Subjects were
not included if any of the following criteria applied:
chronic respiratory insufficiency, cardiac insufficiency,
cancer (chemotherapy, radiotherapy), unstabilized chronic
disease (severe renal or hepatic insufficiency, etc.), or any
chronic severe affection likely to interfere with evaluation
of the study parameters. For the inclusion, subjects were
not allowed to take any drug potentially known to inter-
fere with the evaluation of the study parameters, including
corticoids and immunosuppressive drugs. Consumption
of dietary supplements was forbidden in the last 2 months
before inclusion, as well as regular consumption of pro-
biotic products 1 month before the start of the study.
Study design
The study was a monocentric, randomized, double-blind,
placebo-controlled, parallel arms trial. Subjects were ran-
domly allocated to the probiotic group or to the control
group.
The study lasted 16 weeks and consisted of four con-
sumption periods of 10 d each, followed by 18 d without
consumption of the study products (break period).
At the selection visit, 1 or 2 weeks before initiation of
the study, volunteers underwent a clinical examination
and blood was taken from volunteers to assess safety
parameters and measure of biological inclusion param-
eters. The investigators checked for inclusion criteria
and recorded the subject’s demographic characteristics.
Eligible volunteers were randomly allocated by the in-
vestigator to the probiotic or the placebo group on Visit
1 (V1) of the study, according to the randomization list.
Randomization was done without stratification using
SAS® software version 9.1.3 Service Pack 4 (SAS Insti-
tute Inc., Cary, NC, USA). The randomization list was
prepared before the beginning of the study by a person
not related to the clinical phase, the data management
or statistics. In addition, it was prepared and stored
confidentially. The unblinding envelopes were concealed
from the person responsible for randomization. Dur-
ing the study, four visits were planned: V1 (inclusion
visit, beginning of the 1st product consumption period),
V1 + 10 d (follow-up visit, 10 days after V1, end of the 1st
product consumption period), V2 (follow-up visit,
2 months after V1) and V3 (end-of-study visit, 4 months
after V1) (Fig. 5).
The trial was conducted during the winter season
2010–2011, in the Nantes area, France.
Study products
Study products were presented in the form of food sup-
plements. The probiotic product consisted of B. subtilis
CU1 mixed with excipients (maltodextrin DE14, dicalcic
phosphate, magnesium stearate, colloidal silica). Each
probiotic capsule contained 2.109 spores of B. subtilis
CU1 (LESAFFRE, Marcq en Baroeul, France). The pro-
biotic preparation contains 95 % of B. subtilis spores and
5 % of vegetative cells. Due to spore stability over time,
the probiotic counts were the same at beginning and at
the end of study. The placebo capsule contained only
the excipient mix. Placebo products were indistinguish-
able from the probiotic product in appearance, smell
and taste.
During the four 10-d product consumption periods,
the subjects were instructed to consume daily one cap-
sule of the study product, in the morning (40 min before
breakfast). Otherwise, subjects were asked not to modify
their food habits and they were prohibited from taking
any dietary supplement or food product containing pro-
biotics during the study.
Study endpoints
The primary endpoint was a between products compari-
son of the mean cumulative number of days with CID
(upper and lower respiratory tract infections, gastro-
intestinal tract infections) during the 4 months of study
in the whole population (N = 100). In addition, some
clinical endpoints were analysed in the whole popula-
tion, and biological endpoints in the subset of the first
Fig. 5 Study design. R indicates randomization of the 100 subjects. Blood samples (B), fecal samples (F) and salivary samples (S) concerned a
subset of 44 subjects
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44 subjects (half in the B. subtilis group, half in the
placebo group).
Clinical endpoints included the mean duration of CID,
the intensity of CID, the frequency of CID, and the
percentage of subjects with at least one CID (N = 100).
Biological endpoints included blood immunological
marker concentrations (IL-1beta, IL-4, IL-6, IL-8, IL-10,
IL-12p70, TNF-alpha, IgA, IFN-gamma, at V1 and V1 +
10 d), salivary secretory IgA concentration (at V3), and
fecal secretory IgA concentration (at V1, V1 + 10 d and
V3) (N = 44). At last, the presence of B. subtilis in stools
and the cytotoxicity of stools were analysed in the subset
population (N = 44).
Common infectious disease symptoms
During the 4 months of study, subjects were instructed to
track any CID symptoms they had in a diary. The items
detailed in this diary were: symptoms of gastrointestinal
and upper/lower respiratory tract infections (cough,
hoarseness, sore throat, itchy throat, rhinorrhea, sneezing,
nasal obstruction, conjunctivitis, fatigue, headache, myal-
gia, nausea), body temperature, vomiting, and diarrhoea.
The intensity of each symptom of gastrointestinal and
upper/lower respiratory tract infections was rated on a
4-point scale (from 0: no symptom to 3: severe symp-
tom) whereas fever (i.e., body temperature increased
from at least one degree higher compared to basal
temperature), vomiting and diarrhoea (i.e., more than 3
liquid stools per day) were rated on dichotomous scales
(0 = absence; 3 = experience of the sign). All symptoms
were reviewed by the investigator who determined if
they complied with the diagnosis of a CID or not. When
a CID was diagnosed, a symptomatic score was calcu-
lated on a daily basis, taking into account CID symp-
toms, fever, vomiting, and diarrhoea. This score rates
from 0 to 45 arbitrary units.
For analysis of the mean number of days with CID and
the frequency of CID, all subjects were considered and
“0” was applied to subjects without CID.
Sample collection
Fasting blood samples and stool samples were collected
at V1, V1 + 10 d and V3 among the first 44 randomized
subjects (N = 22 in probiotic group, N = 22 in placebo
group), which corresponded to the first twenty-two sub-
jects enrolled in each group. The randomized repartition
of the subjects was ensured by the randomization list.
Blood was centrifuged for 10 min at 1,000 x g at 4 °C to
separate serum. An aliquot of the serum was used for
IgA determination and a second aliquot was collected
for cytokine analysis. Additionally, saliva samples were
collected at V3 in the same subset. Biological samples,
serum, stools and saliva were stored frozen at −80 °C
until analysis.
Serum, stools and saliva Immunoglobulin A (IgA)
quantification
Serum IgA concentration was measured by Elisa (en-
zyme-linked immunosorbent assay) according to the
manufacturer’s instructions (Hitachi 911, Roche, Basel,
Switzerland). SIgA in stools and saliva were measured
by Elisa (Immuchron AG, Heppenheim, Germany) ac-
cording to the manufacturer’s instructions.
Serum cytokine quantification
Interleukins (IL-1beta, IL-6, IL-8, IL-10, IL-12p70), Tumor
Necrosis Factor alpha (TNF-alpha) and Interferon gamma
(IFN-gamma) were measured using Human Th1/Th2
11plex FlowCytomix immunoassays (eBioscience, Inc) on
the BD Accuri™ C6 Flowcytometer (BD Bioscience) and
ELISA (Ready-SET-Go® eBioscience, Inc.). Furthermore,
human Interferon beta (IFN-beta) was analyzed by Elisa
(R&D Systems, Inc.). All assays were performed according
to the manufacturer’s instructions.
Bacillus spores counts in stools and CU1 strain
identification
Stools samples (2 g) were placed in Stomacher® 400 clas-
sic bags, diluted with 18 ml of sterile physiological saline
water and homogenized for 2 min. Ten ml of dilutions
were heated (80 °C for 10 min) in order to kill bacterial
vegetative cells. Samples were serially diluted 1:10 in
sterile saline and plated on Mueller- Hinton Agar plates
(Difco BD Laboratory, Franklin Lakes, USA) for 24 h at
37 °C for spores counts.
In order to identify CU1 colonies in plates, a molecular
typing method RAPD (Randomly Amplified Polymorphic
DNA) was used. Different types of colonies from every fecal
sample were analyzed in triplicate using the OPL12 primer
that generates a specific profile for the CU1 strain [62].
Assessment of stool cytotoxicity
Stool samples (1 g) were diluted in 5 ml of Dulbecco’s
modified Eagle’s minimum essential medium (DMEM).
After homogenization, samples were centrifuged at 10000 g
for 10 min, then filtered through a 0.2 μm membrane filter
and diluted 1/20 (volume/volume (v/v)) in DMEM media.
Stool cytotoxicity was evaluated by quantifying Vero cell
detachment.
Vero cells were grown in DMEM containing 25 mM
glucose (Sigma-Aldrich), supplemented with 10 % (v/v)
heat-inactivated fetal calf serum (Gibco), 1 % (v/v) nones-
sential amino acids (Sigma), penicillin (100 UI/ml),
streptomycin (100 μg/ml), gentamicin (50 μg/ml) (Sigma).
For maintenance purposes, cells were passed every 3 d,
using Accutase Solution (Sigma). Monolayers were pre-
pared in 48-well tissue culture plates (Greiner Bio One,
Germany) by seeding 5.104 cells per well. Experiments
and cell maintenance were carried out at 37 °C in a 5 %
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CO2-95 % air atmosphere. Fully confluent cells (3–4 d in
culture) were used throughout.
Briefly, confluent cells were co-incubated with the dif-
ferent stool samples at 37 °C for 2 h and then cells were
washed with phosphate-buffered saline (PBS), fixed for
1 min with 2 % (v/v) formaldehyde in PBS, washed again
in PBS and stained with 500 μl of crystal violet solution
(0.13 % crystal violet, 5 % ethanol, and 2 % formaldehyde
in PBS w/v/v) for 20 min at room temperature. After
being exhaustively washed with PBS to remove stain
excess, samples were treated for 1 h with freshly pre-
pared 50 % ethanol in PBS (v/v) at room temperature.
Absorbance was measured at 650 nm in a Thermo Max
Microplate spectrophotometer reader. Percentage of at-
tached cells was calculated as: 100 x (A/Ac), where A is
the absorbance of treated cells and Ac is the absorbance
of untreated control cells. As positive control a diluted
supernatant of Clostridium difficile VPI 10463 was used.
Safety
Adverse events were collected during the study by inves-
tigators and reported in the case report forms of each
subject. The investigators had also to evaluate imputabil-
ity of any adverse event to the study products.
Statistical analysis
Based on previous pilot clinical studies, sample size was
calculated to detect an intergroup difference of 3 d in CID
episodes (with Standard Deviation (SD): 5 d), using a two-
tailed t-test at the significance level of 0 · 05. Forty-eight
subjects were required in each group to provide 80 % stat-
istical power. To account for potential drop-outs, it was
planned to include fifty subjects in each group.
Data were analysed using SAS® software version 9.1.3 Ser-
vice Pack 4 (SAS Institute Inc., Cary, NC, USA). Results are
expressed as Mean (SD). Significance was set at P < 0.05.
The mean number of days with CID and other clin-
ical outcomes (mean duration, intensity, and frequency
of CID) were compared between groups using the
Wilcoxon-Mann-Whitney’s test or Savage’s test (ac-
cording to the asymmetry of data). The percentage of
subjects with at least one CID was compared between-
group using a logistic regression model. Immunological
variables with a normal distribution (plasma, salivary
and fecal IgA, IL-6, IL-8, IL-10, IL-12, and stool cyto-
toxicity) were compared using Student’s t-test for
between-group analysis and Student’s paired t-test for
within-group analysis. For criteria which do not respect
normal distribution (IFN-gamma, TNF-alpha, IL-1 and
IL-4), a Wilcoxon-Mann-Whitney’s test was applied for
between group analysis, and completed with Savage’s
test for IL-1 and IL-4 due to dissymmetry of these
biological parameters. Within-group analysis was per-
formed using Wilcoxon’s paired test. The number of
subjects with at least one side-effect in each group
(probiotic and placebo groups) was compared using
Chi-square test.
Following this primary analysis, some post-hoc ana-
lyses were performed. The first analysed the clinical out-
comes reported in the subset of 44 subjects (number of
days with CID, mean duration of CID, intensity of CID,
frequency of CID, and percentage of subjects with at
least one CID). The second post-hoc analysis applied on
the clinical outcomes in subjects who reported at least
one symptom of upper/lower respiratory tract infections,
whatever this symptom was or not associated to a symp-
tom of gastrointestinal infection. This latter analysis was
performed in the whole population of 100 subjects and
in the subset of 44 subjects. The statistical models were
identical to the ones applied for the primary analysis.
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